Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Jul;39(7):1445–1453. doi: 10.1128/aac.39.7.1445

Disposition of S-1108, a new oral cephem antibiotic, and metabolic fate of pivalic acid liberated from [pivaloyl-14C]S-1108 in rats and dogs.

K Mizojiri 1, S Futaguchi 1, R Norikura 1, Y Katsuyama 1, T Nagasaki 1, T Yoshimori 1, M Nakanishi 1
PMCID: PMC162760  PMID: 7492083

Abstract

[pivaloyl-14C]S-1108, which is 14C labeled at the pivalic acid moiety of the pivaloyloxymethyl side chain of S-1108, was administered orally to rats and dogs, and the disposition of pivalic acid cleft from S-1108 was examined. Besides pivaloylcarnitine and pivaloylglucuronide, pivaloylglycine was identified in dog urine as a metabolite of pivalic acid by thin-layer chromatography and high-performance liquid chromatography analysis. The concentrations in the plasma of rats to which doses of 6.65, 26.6, and 532 mg/kg of body weight were administered showed dose-proportionate levels. The radioactivity was eliminated rapidly, with a half-life of approximately 3 h until 24 h at both the 6.65- and 26.6-mg/kg doses. Free pivalic acid in plasma accounted for more than 80% of the concentration of radioactivity. Radioactivity was distributed throughout the body and was eliminated quickly at a rate similar to that of radioactivity from plasma. Most of the absorbed radioactivity was excreted in the urine, and it was completed within 24 h after administration. In dogs, the half-life of radioactivity in plasma was longer than that in the rats. The ratio of free pivalic acid in plasma was 60 to 70% of the radioactivity in plasma. The concentration of radioactivity in the liver, cortex of the kidney, and skeletal muscle 144 h after oral dosing was more than 10 times higher than the concentration in plasma for all doses. Urinary excretion in dogs was slower than that in rats. The differences in the disposition of pivalic acid between dogs and rats may account for differences in the degree of skeletal muscle disorders. The safety in humans of S-1108 given at 200 mg three times a day is discussed in relation to the metabolic formation of the carnitine conjugate of pivalic acid and the reduction of the carnitine concentration in plasma.

Full Text

The Full Text of this article is available as a PDF (420.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Diep Q. N., Bøhmer T., Schjerven L. Reduced carnitine and ketogenesis in the pivampicillin treated rat. Biochem Pharmacol. 1992 Sep 25;44(6):1226–1228. doi: 10.1016/0006-2952(92)90391-u. [DOI] [PubMed] [Google Scholar]
  2. Eggers N. J., Doust K. Isolation and identification of probenecid acyl glucuronide. J Pharm Pharmacol. 1981 Feb;33(2):123–124. doi: 10.1111/j.2042-7158.1981.tb13731.x. [DOI] [PubMed] [Google Scholar]
  3. Faed E. M., McQueen E. G. Separation of two conjugates of clofibric acid (CPIB) found in the urine of subjects taking clofibrate. Clin Exp Pharmacol Physiol. 1978 Mar-Apr;5(2):195–198. doi: 10.1111/j.1440-1681.1978.tb00671.x. [DOI] [PubMed] [Google Scholar]
  4. Gregus Z., Fekete T., Varga F., Klaassen C. D. Effect of valproic acid on glycine conjugation of benzoic acid. J Pharmacol Exp Ther. 1993 Dec;267(3):1068–1075. [PubMed] [Google Scholar]
  5. Hjelle J. J. Hepatic UDP-glucuronic acid regulation during acetaminophen biotransformation in rats. J Pharmacol Exp Ther. 1986 Jun;237(3):750–756. [PubMed] [Google Scholar]
  6. Holme E., Greter J., Jacobson C. E., Lindstedt S., Nordin I., Kristiansson B., Jodal U. Carnitine deficiency induced by pivampicillin and pivmecillinam therapy. Lancet. 1989 Aug 26;2(8661):469–473. doi: 10.1016/s0140-6736(89)92086-2. [DOI] [PubMed] [Google Scholar]
  7. Holme E., Jodal U., Linstedt S., Nordin I. Effects of pivalic acid-containing prodrugs on carnitine homeostasis and on response to fasting in children. Scand J Clin Lab Invest. 1992 Sep;52(5):361–372. doi: 10.3109/00365519209088371. [DOI] [PubMed] [Google Scholar]
  8. Illing H. P., Wilson I. D. pH dependent formation of beta-glucuronidase resistant conjugates from the biosynthetic ester glucuronide of isoxepac. Biochem Pharmacol. 1981 Dec 15;30(24):3381–3384. doi: 10.1016/0006-2952(81)90620-1. [DOI] [PubMed] [Google Scholar]
  9. Ishikura K., Kubota T., Minami K., Hamashima Y., Nakashimizu H., Motokawa K., Kimura Y., Miwa H., Yoshida T. Synthesis and structure-activity relationships of 7 beta-[(Z)-2-(2- aminothiazol-4-yl)-3-(substituted)-2-propenoylamino]-3-cephems with C-3 substitutions. J Antibiot (Tokyo) 1994 Apr;47(4):466–476. doi: 10.7164/antibiotics.47.466. [DOI] [PubMed] [Google Scholar]
  10. Melegh B., Kerner J., Bieber L. L. Pivampicillin-promoted excretion of pivaloylcarnitine in humans. Biochem Pharmacol. 1987 Oct 15;36(20):3405–3409. doi: 10.1016/0006-2952(87)90318-2. [DOI] [PubMed] [Google Scholar]
  11. Melegh B., Kerner J., Jaszai V., Bieber L. L. Differential excretion of xenobiotic acyl-esters of carnitine due to administration of pivampicillin and valproate. Biochem Med Metab Biol. 1990 Feb;43(1):30–38. doi: 10.1016/0885-4505(90)90005-l. [DOI] [PubMed] [Google Scholar]
  12. Melegh B., Sumegi B., Sherry A. D. Preferential elimination of pivalate with supplemental carnitine via formation of pivaloylcarnitine in man. Xenobiotica. 1993 Nov;23(11):1255–1261. doi: 10.3109/00498259309059436. [DOI] [PubMed] [Google Scholar]
  13. Nakashima M., Uematsu T., Oguma T., Yoshida T., Mizojiri K., Matsuno S., Yamamoto S. Phase I clinical studies of S-1108: safety and pharmacokinetics in a multiple-administration study with special emphasis on the influence on carnitine body stores. Antimicrob Agents Chemother. 1992 Apr;36(4):762–768. doi: 10.1128/aac.36.4.762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Quistad G. B., Staiger L. E., Schooley D. A. Environmental degradation of the miticide cycloprate (hexadecyl cyclopropanecarboxylate). 4. Beagle dog metabolism. J Agric Food Chem. 1978 Jan-Feb;26(1):76–80. doi: 10.1021/jf60215a010. [DOI] [PubMed] [Google Scholar]
  15. Shimizu K., Saito A., Shimada J., Ohmichi M., Hiraga Y., Inamatsu T., Shimada K., Tanimura M., Fujita Y., Nishikawa T. Carnitine status and safety after administration of S-1108, a new oral cephem, to patients. Antimicrob Agents Chemother. 1993 May;37(5):1043–1049. doi: 10.1128/aac.37.5.1043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Totsuka K., Shimizu K., Konishi M., Yamamoto S. Metabolism of S-1108, a new oral cephem antibiotic, and metabolic profiles of its metabolites in humans. Antimicrob Agents Chemother. 1992 Apr;36(4):757–761. doi: 10.1128/aac.36.4.757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Upton R. A. Simple and reliable method for serial sampling of blood from rats. J Pharm Sci. 1975 Jan;64(1):112–114. doi: 10.1002/jps.2600640123. [DOI] [PubMed] [Google Scholar]
  18. Vickers S., Duncan C. A., White S. D., Ramjit H. G., Smith J. L., Walker R. W., Flynn H., Arison B. H. Carnitine and glucuronic acid conjugates of pivalic acid. Xenobiotica. 1985 Jun;15(6):453–458. doi: 10.3109/00498258509045018. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES